Kerry Chrysiliou v B. Braun Melsungen AG

Link copied
Case Copied 53 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Kerry Chrysiliou v B. Braun Melsungen AG [2016] APO 25

Patent Application:                2011287917

Title:Needle Safety Device and Assembly

Patent Applicant:                   B. Braun Melsungen AG

Opponent:  Kerry Chrysiliou

Delegate:  M. G. Kraefft

Decision Date:  5 May 2016

Hearing Date:  22 March 2016, in Canberra

Catchwords:  PATENTS – section 59 – opposition to grant of a patent – whether evidence in reply was properly evidence in reply – evidence found to be properly in reply – priority date valid – whether claimed invention was novel – prior use not established – claims novel over prior art documents and over alleged prior use – whether invention described fully – whether claims fairly based and clear – opposition failed on all grounds.

Representation:  Patent applicant:  Mr Edward J Heerey, of counsel, assisted by Mr Michael Cooper and Mr Mathew Lucas, patent attorneys, Davies Collison Cave, and Mr Kevin Woehr of B. Braun Melsungen AG.

Opponent:  Ms Kerry Chrysiliou, patent attorney, Chrysiliou IP.

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Application:                2011287917

Title:Needle Safety Device and Assembly

Patent Applicant:                   B. Braun Melsungen AG

Date of Decision:                   5 May 2016

DECISION

The opponent’s evidence in reply is properly evidence in reply.  Nonetheless the opposition fails on all grounds raised in this opposition.

Subject to appeal, I direct the application proceed to grant.

Costs in accordance with Schedule 8 awarded against the opponent, Kerry Chrysiliou.

REASONS FOR DECISION

BACKGROUND

  1. B. Braun Melsungen AG (“the applicant”) filed patent application 2011287917 on 26 July 2011.  The application claims an earliest priority date of 5 August 2010 from a US patent application (“the priority document”).  Application 2011287917 was advertised accepted on 3 July 2014.

  2. Kerry Chrysiliou (“the opponent”) filed a notice of opposition to the grant of a patent on 3 October 2014.  A statement of grounds and particulars followed on 5 January 2015.

  3. The parties completed the evidentiary stages on 14 September 2015.

    SPECIFICATION

  4. The specification describes the background to the alleged invention generally relating to needle safety assemblies and safety intravenous catheters (“IVCs”) and, in particular, to a safety IVC in which the needle tip is automatically covered after needle withdrawal to prevent unintended needle stick with the needle tip.

  5. IVCs are primarily used to administer fluids directly into a patient’s vascular system.  Typically, a catheter is inserted into a patient’s vein by a health care worker.  Immediately after the withdrawal of the needle from the patient’s vein, the exposed needle tip creates a danger of an accidental needle stick occurring, which leaves the health care worker vulnerable to the transmission of various dangerous blood-borne pathogens.

  6. The specification states this danger has led to the development of safety IVCs that cover or hide the needle tip using several different means.  However, some safety IVCs that have been developed sometimes fail to prevent unintended needle sticks from occurring.  For example, in some safety IVCs, the turning of the needle during removal may cause the needle tip to slide out…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Kerry Chrysiliou v B. Braun Melsungen AG and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2016] APO 25
Decision Date

CaseChat Overview and Summary

The case involves an opposition to the grant of a patent application 2011287917 filed by B. Braun Melsungen AG, which claims a needle safety device and assembly. Kerry Chrysiliou opposed the grant, arguing that the invention was not novel, did not involve an inventive step, and that the complete specification did not describe the invention fully and that the claims were not fairly based or clear. The court examined the evidence provided by both parties and concluded that the opponent's evidence in reply was properly in reply. The court found that the claims of the patent application were novel over the prior art documents cited by the opponent and that the complete specification described the invention fully, and that the claims were fairly based and clear.

The court also found that the priority date of the claims was valid and that the invention was not anticipated by prior use. The court concluded that the claims of the patent application were novel over the prior art and that the invention met the requirements for patentability under the Patents Act 1990. The opposition was unsuccessful on all grounds, and the court directed that the application proceed to grant, subject to appeal. The court awarded costs in accordance with Schedule 8 against the opponent, Kerry Chrysiliou.

Background

Background to the litigation

The case involves a patent application for a needle safety device and assembly, filed by B. Braun Melsungen AG on 26 July 2011, claiming priority from a US patent application dated 5 August 2010. The application was advertised accepted on 3 July 2014. Kerry Chrysiliou filed a notice of opposition to the grant of the patent on 3 October 2014, with a statement of grounds and particulars following on 5 January 2015. The parties completed the evidentiary stages on 14 September 2015. The invention pertains to a needle safety assembly that automatically covers the needle tip after withdrawal to prevent accidental needle sticks, which are a risk for healthcare workers. The device includes a needle guard with specific dimensional and functional features designed to securely hold the needle tip after use.

This case involves an opposition to the grant of a patent brought by Kerry Chrysiliou against B. Braun Melsungen AG before the Australian Patent Office. The opposition was filed on 3 October 2014, and the statement of grounds and particulars followed on 5 January 2015. The matter proceeded through evidentiary stages, with the final submissions and evidence provided by 14 September 2015. The hearing took place on 22 March 2016, and the decision was issued on 5 May 2016. The decision found in favour of the patent applicant, B. Braun Melsungen AG, and directed that the application proceed to grant, subject to appeal. Costs were awarded against the opponent, Kerry Chrysiliou, in accordance with Schedule 8.

Decision

Reasons for decision

Issues
1. Whether the opponent’s evidence in reply was properly evidence in reply.
2. Whether the claims of the patent application are entitled to the earliest claimed priority date of 5 August 2010.
3. Whether the invention claimed in the patent application is novel over the prior art.
4. Whether the invention claimed in the patent application was publicly used before the priority date.
5. Whether the complete specification describes the invention fully and enables a person skilled in the art to produce the invention.
6. Whether the claims of the patent application are fairly based and clear.

Held
1. The opponent’s evidence in reply was properly evidence in reply.
2. The claims of the patent application are entitled to the earliest claimed priority date of 5 August 2010.
3. The invention claimed in the patent application is novel over the prior art.
4. The invention claimed in the patent application was not publicly used before the priority date.
5. The complete specification describes the invention fully and enables a person skilled in the art to produce the invention.
6. The claims of the patent application are fairly based and clear.

Ratio Decidendi

Legal Principle Established

The case involved an opposition to the grant of a patent for a needle safety device and assembly. The opponent argued that the patent application failed on various grounds, including novelty, sufficiency of description, and clarity of claims. The delegate found the opponent's evidence in reply to be properly in reply, addressing the applicant's evidence. The delegate ruled on each ground of opposition as follows: The delegate held that the opponent's evidence in reply was properly evidence in reply, despite some contention from the applicant. The evidence in reply was found to be generally responsive to the applicant's evidence in answer, addressing specific interpretations of prior art and design features. The delegate concluded that the claims were entitled to the earliest claimed priority date of 5 August 2010, finding that the claims were fairly based on the matter disclosed in the priority document. The delegate found the invention to be novel over the cited prior art documents, as none of the prior art disclosed the specific dimensional relationships and functional features claimed in the application. The delegate determined that the opponent had not established prior use of the invention before the priority date, as the evidence provided was insufficient and uncorroborated. The delegate found that the complete specification described the invention fully and enabled a person skilled in the art to produce the invention, including the specific features of the close fit ratio and the method of assembly. Lastly, the delegate held that the claims were fairly based and clear, rejecting the opponent's contentions regarding the description and support for the claimed features. The ratio decidendi of the decision is that the invention claimed in the patent application is novel, has a full and enabling description, and clear claims, thus satisfying the requirements for patentability.